Evitria

Executive Summary

Evitria is a Swiss biotechnology company established in 2006 that specializes in high-quality recombinant antibody expression services using Chinese Hamster Ovary (CHO) cells. The company offers a fast-turnaround, project-based model tailored to therapeutic antibody development, including bispecific, afucosylated, and Fc-silenced formats. By leveraging its proprietary CHO expression platform, Evitria enables clients to accelerate biologics from discovery through development, providing a reliable and scalable solution for preclinical and clinical-stage antibody production. As a private entity based in Zurich, Switzerland, the company serves the global biopharma industry with a focus on speed and customization. Evitria's competitive advantage lies in its specialized expertise in complex antibody formats and its ability to deliver high-yield, high-quality antibodies within accelerated timelines. The company's service model reduces the time from gene to purified antibody, supporting clients in de-risking and expediting their drug development programs. While Evitria operates as a service provider rather than a drug developer, its technology is critical to the biotech ecosystem. The company's growth is driven by increasing demand for novel antibody therapeutics and outsourcing of manufacturing to specialized CROs. With no disclosed funding or valuation, Evitria remains a niche but essential player in the antibody expression space.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Service Portfolio to Next-Generation Antibody Formats70% success
• 2027Strategic Collaboration with Top-20 Pharma for Antibody Development50% success